Phathom Pharmaceuticals Q2 EPS $(0.84) Beats $(1.00) Estimate; Cash Balance Of $248.8M Is Expected To Provide Cash Runway Into 2025
Portfolio Pulse from Benzinga Newsdesk
Phathom Pharmaceuticals reported Q2 losses of $(0.84) per share, beating the analyst consensus estimate of $(1.00) by 16 percent. This is a 36.84 percent increase over losses from the same period last year. The company's cash balance of $248.8M is expected to provide a cash runway into 2025.
August 10, 2023 | 12:18 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Phathom Pharmaceuticals reported better than expected Q2 earnings and has a strong cash position, which is expected to last until 2025.
Phathom Pharmaceuticals reported better than expected Q2 earnings, which is generally a positive signal for the stock. Additionally, the company's strong cash position reduces financial risk and provides stability for future operations, which is also positive for the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100